BCell

BOSTON and SHANGHAI, China and LAUSANNE, Switzerland, July 24, 2023 (GLOBE NEWSWIRE) -- Overland ADCT BioPharma, a joint venture of Overland Pharmaceuticals (CY) Inc. and ADC Therapeutics SA (NYSE: ADCT), today announced that the China…

New York, USA, May 31, 2023 (GLOBE NEWSWIRE) -- B-Cell Lymphoma Clinical Trial Pipeline Insights: DelveInsight Evaluates a Robust Pipeline as 160+ Influential Pharma Players to Set Foot in the Domain The prevalence of B-cell lymphoma…

<!-- Name:DistributionId Value:8744827 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False --> <!-- Name:IcbCode Value:4570 -->…

Goal is to report initial SC291 clinical data this year Goal is to submit a second IND from the platform this year for SC262, a hypoimmune-modified CD22-targeted allogeneic CAR T therapy SEATTLE, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Sana…

SAN DIEGO, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that…

The first patient completed the 28-day Dose Limiting Toxicity (DLT) observation period without complication NEW YORK, Dec. 22, 2022 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage…

Data demonstrated robust anti-tumor activity of BMF-219 and mechanistic evidence for novel inhibition of menin protein in preclinical models of Diffuse Large B-cell Lymphoma (DLBCL) and multiple myeloma (MM).BMF-219 displayed single agent…

UCART20x22 is Cellectis’ first allogeneic dual CAR T, targeting CD20 and CD22 simultaneously UCART20x22 is Cellectis’ first product candidate fully designed, developed and manufactured in-house Phase 1/2a clinical trial NatHaLi-01…

SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose…

-- Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes -- Study will evaluate SYK inhibitor both in patients with wild-type disease and those with tumors that harbor MYD88 or…